Catalyst Pharmaceuticals Provides an Update of 2015 Goals

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Catalyst Pharmaceuticals Provides an Update of 2015 Goals for Its Product Portfolio

Pre-NDA Meeting with the FDA

Firdapse NDA Submission

Developing Regulatory Strategy for Firdapse for Congenital Myasthenic Syndrome

Hosting 1x1 Meetings in San Francisco January 12-15

CORAL GABLES, Fla., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the company's 2015 goals for its product portfolio. The Company will be hosting 1x1 meetings this week in conjunction with The Trout Group Management Access Conference in San Francisco, January 12-15. The Company's presentation materials will be available on the "Investors" section of the Company's website, www.catalystpharma.com .

Firdapse ™ has been granted Breakthrough Therapy and Orphan Drug Designations by the FDA for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) and reported positive results from its Phase 3 clinical trial evaluating Firdapse ™ for the treatment of LEMS in September 2014. The Company has also initiated an expanded access program (EAP) under which patients with LEMS and Congenital Myasthenic Syndrome (CMS), who meet the inclusion/exclusion requirements, have access to Firdapse ™ via the EAP, at no charge to the patients. Catalyst expects to meet with the FDA for its pre-NDA meeting in Q1 2015, to begin its rolling NDA submission for Firdapse ™ for the treatment of LEMS sometime thereafter and to complete its NDA submission sometime in Q3 2015. Catalyst recently promoted David D. Muth to Chief Commercial Officer as it continues to build out its commercial team ahead of a potential launch of the product in 2016.

Catalyst is continuing to develop CPP-115, a novel GABA-aminotransferase inhibitor, for a broad range of central nervous system indications, such as infantile spasms, epilepsy, Tourette Syndrome and Post Traumatic Stress Disorder (PTSD). The Company expects initial top line results from an academic investigator sponsored proof-of-concept study evaluating another GABA-aminotransferase inhibitor, vigabatrin, for the treatment of Tourette's Disorder during the second quarter of 2015. It also expects to obtain the results of its Phase 1 MAD study of CPP-115 during the second quarter of 2015. Additionally, Catalyst plans to explore other selected diseases in which modulation of GABA levels might be beneficial.

"This year will provide significant anticipated milestones and achievements for the company and our pipeline as we move towards an NDA filing for Firdapse ™ this summer," said Patrick J. McEnany, Chief Executive Officer of Catalyst. "Along with the commencement of the expanded access program, we continue to focus on our pre-commercial activities for Firdapse ™ in the LEMS community, as we prepare for an anticipated launch of the product in the first half of 2016, pending FDA approval. Finally, exploration of additional indications like Congenital Myasthenic Syndrome for Firdapse ™ may provide further opportunities to expand the market and serve additional patients with unmet medical needs."

Anticipated 2015 Goals

Catalyst expects to achieve the following key milestones in the upcoming year:

  • Conduct Pre-NDA meeting . Catalyst expects to hold a pre-NDA meeting with the FDA in Q1 2015. 
  • Submit Firdapse™ NDA to FDA . Catalyst expects to complete its renal safety study and full toxicology program for Firdapse ™ in Q2 2015, with an anticipated completion of an NDA submission to the FDA by Q3 2015. 
  • Complete launch of Firdapse™ expanded access program. Catalyst is currently enrolling LEMS and CMS patients in the expanded access program, which will provide Firdapse ™ at no charge to patients who meet the inclusion/exclusion requirements. 
  • Complete all pre-commercialization activities required for successful Firdapse ™ launch . The Company will continue to focus on pre-commercial activities ahead of an estimated approval / launch of Firdapse™ in 1H 2016.  
  • CPP-109: Top-line results from Tourette's Disorder. An academic investigator sponsored study evaluating CPP-109 for the treatment of Tourette's Disorder is ongoing at Mt. Sinai, in New York, and Catalysts expects to announce topline results in the first half of 2015. 
  • CPP-115: Catalyst expects to announce topline results from a Phase 1 multiple dose safety and tolerance study in the first half of 2015 .
  • Exploration of additional indications for Firdapse™.  Catalyst plans to continue to explore additional indications including Congenital Myasthenic Syndrome and refractory Myasthenia Gravis.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette Syndrome. Catalyst's lead candidate, Firdapse™ for the treatment of LEMS, recently completed testing in a global, multi-center, pivotal Phase 3 trial resulting in positive top-line data. Firdapse™ for the treatment of LEMS has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). Firdapse™ is the first and only European approved drug for symptomatic treatment in adults with LEMS.

Catalyst is also developing CPP-115 to treat infantile spasms, epilepsy and other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder and Tourette Syndrome. CPP-115 has been granted U.S. orphan drug designation for the treatment of infantile spasms by the FDA and has been granted E.U. orphan medicinal product designation for the treatment of West Syndrome by the European Commission.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including whether the receipt of breakthrough therapy designation for Firdapse™ will expedite the development and review of Firdapse™ by the FDA or the likelihood that the product will be found to be safe and effective, whether an NDA for Firdapse™ will ever be accepted for filing by the FDA, the timing of any such NDA filing or acceptance, whether Catalyst will be the first company to receive approval for amifampridine (3,4-DAP), giving it 7-year marketing exclusivity for its product, whether CPP-115 will be determined to be safe for humans, whether CPP-115 will be determined to be effective for the treatment of infantile spasm, post-traumatic stress disorder, Tourette Syndrome or any other indications, whether any of Catalyst's product candidates will ever be approved for commercialization or successfully commercialized, and those other factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2013 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Investor Contact Brian Korb The Trout Group LLC (646) 378-2923 Media Contacts David Schull Matt Middleman, M.D. Russo Partners (212) 845-4271 (212) 845-4272 Company Contact Patrick J. McEnany Catalyst Pharmaceuticals Chief Executive Officer (305) 529-2522

Scroll down for more posts ▼

Top 10 Most Recent News Articles

COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 61

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
InPHRED's Award Brings 1310 nm VCSELs Into Focus at IEEE

Updated Category News Views 146

A stubborn mirror problem just put InPHRED on the photonics map. InPHRED, founded in 2023, took the Best Technology award at the inaugural 2026 IEEE Photonics Conference Start-Up Competition, selected from seven finalists. That is a meaningful industry pat on the back, particularly because the company is aiming at a real engineering headache rather than waving around...

Continue Reading
Stardock Fences 7 Targets Messy Windows Desktops Everywhere

Updated Category News Views 18

A cluttered Windows desktop is a tiny tax on attention, and Stardock has spent three decades selling people a way around it. Fences 7, released November 18, 2026, is the latest swing: a Windows 11-focused update that combines cosmetic polish with a genuinely practical privacy feature. This is not grand enterprise software, and nobody should pretend a $10 desktop utility...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 246

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 196

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 87

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
Thanksgiving Dog Safety Is a Pet Care Reality Check

Updated Category News Views 9

A crowded Thanksgiving kitchen can turn a well-behaved dog into a scavenger with lousy odds. Camp Bow Wow’s holiday guidance is not pretending the meal itself is the problem; the trouble is that a house full of distracted people, rich food and unsecured trash creates a pile of easy mistakes. For pet owners, that is a fair reminder. For anybody watching the pet-care...

Continue Reading
ActivTrak's Fast 500 Rank Needs Investor Perspective

Updated Category News Views 35

Rank 488 is the sort of trophy that deserves a raised eyebrow, not confetti. ActivTrak made Deloitte's 2026 Technology Fast 500 after posting 101.1% revenue growth from 2022 through 2025, its sixth appearance on the list since 2020. That is real progress, and repeat recognition says this was not a one-quarter sugar high. Still, a Fast 500 ranking is a growth screen, not a...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 34

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 116

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into Abacus Global Management Inc. Stock

Updated Category News Views 231

Wolf Popper LLP Initiates Investigation for Investors In response to potential investor claims, Wolf Popper LLP has begun an investigation concerning the common stock of Abacus Global Management, Inc. (ABL). This action comes in light of significant recent developments that have raised concerns among shareholders. Background on Abacus Global Management Abacus Global...

Continue Reading
LM Funding America Inc. Reports Q3 2024 Results and Outlook

Updated Category News Views 115

Business Update and Financial Highlights LM Funding America, Inc. (NASDAQ: LMFA) has recently shared its financial results for the third quarter of 2024. This Tampa-based company focuses on cryptocurrency mining and technological finance solutions, showcasing significant strategic developments in its operations. Bitcoin Holdings and Revenue Performance As of September 30,...

Continue Reading
Siete Foods' Juntos Fund Celebrates 15 Latino-Owned Businesses

Updated Category News Views 239

Siete Foods launched its Juntos Fund back in 2024, dishing out a hefty $300,000 to uplift Latino small business owners. This initiative aimed at breaking down barriers for Latino entrepreneurs who often struggle to secure the financial backing they need. The winners? A mix of vibrant eateries and innovative food ventures that embody the rich essence of Latino culture...

Continue Reading
Discover the Fascinating Marilyn Monroe in New Documentary

Updated Category News Views 319

Big Screen Entertainment Group Unveils Marilyn Monroe Documentary Big Screen Entertainment Group (OTC: BSEG) has generated excitement with the release of its first trailer for an upcoming documentary focusing on the legendary actress Marilyn Monroe. This film, titled "Hollywood Legends: The Marilyn Monroe Story," promises to be a captivating tribute that delves into not...

Continue Reading
Transforming Dealerships: FrogData's New Marketing Solution

Updated Category News Views 120

FrogData Introduces FixedOps Velocity for Dealerships FrogData, a leader in advanced data analytics for the automotive industry, has recently launched a groundbreaking marketing solution called FixedOps Velocity. This innovative platform is aimed at helping dealership service departments enhance their marketing strategies significantly. The announcement comes just ahead...

Continue Reading